Muscle Loss on GLP-1s and Why It Matters If You Stop

Written by Dr. Scott Gmora, MD, FRCSC, FACS — bariatric and metabolic surgeon. About Dr. Gmora

Yes, weight lost on semaglutide or tirzepatide includes some lean tissue alongside fat. In the trials that measured it with body scans, roughly three quarters of the weight lost was fat and roughly a quarter was lean mass. That ratio is not something the medication does to you. It is close to what happens with dieting, and close to what happens after sleeve gastrectomy. What changes the picture is what you do while the weight is coming off, and what happens to that tissue if the weight returns.

Before going further: there is a version of this topic circulating online that treats these medications as though they were quietly harming people. The evidence does not support that framing, and someone stopping an effective treatment because an article frightened them is a far worse outcome than anything described here. Medication decisions belong with the person who prescribes yours.

"Lean mass" and "muscle" are not the same measurement

Almost every number in this discussion comes from DXA, the same scan used for bone density. DXA sorts the body into three buckets: fat mass, bone, and lean soft tissue. That third bucket is where the confusion starts.

Lean soft tissue includes muscle, but it also includes water, stored glycogen, liver, gut, connective tissue and blood. Glycogen holds roughly three grams of water for every gram of glycogen, so the early weeks of any substantial calorie deficit shed a meaningful amount of "lean mass" that is really water and stored carbohydrate. Organ tissue shrinks too. Work modelling how much of calorie-restriction weight loss is genuinely skeletal muscle concludes that fat-free mass overstates muscle loss, because a substantial share of the fat-free mass that goes is organ and other non-muscle tissue rather than muscle itself, a point made in a 2024 analysis in the Journal of the Endocrine Society. Imaging work presented to regulators has also shown that DXA counts a portion of adipose tissue as lean mass, adding further noise.

So the headline figures overstate muscle loss. They do not make it zero.

What the trials actually measured

The clearest dataset comes from the tirzepatide body composition substudy, where 160 participants had DXA scans at the start and at 72 weeks. Body weight fell 21.3%, fat mass 33.9%, and lean mass 10.9%. In the placebo group the figures were 5.3%, 8.2% and 2.6%. Of the weight lost, about 75% was fat and about 25% was lean mass — and that split was essentially the same in both groups. The ratio belongs to weight loss itself, not to the drug.

The semaglutide body composition substudy enrolled 140 participants — 95 on semaglutide 2.4 mg and 45 on placebo — and over 68 weeks the semaglutide arm lost 19.3% of total fat mass and 27.4% of visceral fat, with lean mass rising as a proportion of total body weight even though the absolute amount fell. That analysis was reported as a conference abstract rather than a full paper.

You will also see reviews that calculate a higher lean-mass share for that trial — up to around 40% — and compare the magnitude to a decade or two of age-related muscle loss. Those comparisons get quoted widely. They rest on DXA lean mass rather than measured muscle, which is precisely the limitation above.

Function is the more useful question, and here the data are cautiously reassuring. A twelve-month cohort study of patients on semaglutide found grip strength improved by about 4 kg, and the proportion meeting criteria for sarcopenic obesity fell from 49% to 33%. When experts and regulators reviewed this evidence together, they did not reach consensus that lean mass loss during obesity treatment is inherently harmful, while flagging genuine concern for older adults and for people who already have low muscle mass, and noting that long-term functional data are thin.

An honest summary: the tissue loss is real, the muscle-specific loss is smaller than the headlines suggest, and whether it causes harm in an otherwise healthy middle-aged adult is not settled. Individual outcomes differ.

The same thing happens after surgery

This is the part I think patients deserve to hear from a surgeon rather than from a comment section. The systematic review of body composition after bariatric surgery found that lean body mass accounted for about 23% of total weight lost at twelve months, and fat-free mass about 21%, with the share running higher — 30% to 33% — across the first three months, when the weight comes off fastest. Skeletal muscle specifically accounted for about 8%.

That is not a footnote in bariatric care. It is the reason protein targets, supplementation and lab monitoring belong in long-term aftercare rather than being treated as optional extras, and it is one of the trade-offs that belongs in any honest conversation about sleeve gastrectomy. Any treatment that moves weight quickly moves lean tissue with it. Medication is not an outlier.

Why it matters more once treatment stops

Two mechanisms are worth understanding.

The first is metabolic. Muscle is metabolically active tissue, so losing it lowers energy expenditure. Beyond that, energy expenditure after weight loss tends to sit somewhat lower than body composition alone would predict — a phenomenon described as adaptive thermogenesis. The size of that gap varies between people and appears to shrink once weight has been stable for a while, so it is a headwind rather than a wall.

The second is the composition of regain. In the weight-cycling literature, fat tends to be restored ahead of lean tissue, and fully rebuilding lean tissue tends to involve overshooting fat along the way. The practical implication is that returning to a previous weight does not necessarily mean returning to a previous body composition.

Here I have to be careful about what is known. Regain after stopping is well documented: participants regained roughly two thirds of their lost weight in the year after semaglutide was withdrawn, and in the tirzepatide withdrawal trial, 82.5% of those switched to placebo after losing at least 10% during the lead-in phase had regained a quarter or more of that loss by week 88. What those trials did not report is the tissue composition of the regained weight. Applying the weight-cycling physiology above is a reasonable inference. It is still an inference, and I would rather say so than present it as established.

What it argues for is protecting lean tissue while weight is coming off, not attempting to repair the situation afterwards. If you are already thinking about this stage, what happens to weight after stopping a GLP-1 covers the broader picture, and when a GLP-1 stops working deals with plateaus on treatment.

What actually protects lean tissue

Two things have evidence behind them, and neither is exotic.

Protein, spread across the day. Guidance for people losing weight on incretin-based treatment sits at roughly 1.25 to 1.5 times the recommended dietary allowance — about 1.0 to 1.2 g per kg of body weight per day, or 1.5 g per kg of fat-free mass — with at least 25 to 30 g at each meal rather than concentrated at dinner. After bariatric surgery, the guideline floor — set in the 2019 joint update from the American endocrine and bariatric surgery societies — is at least 60 g per day, with intakes up to 1.5 g/kg of ideal body weight assessed individually. The genuine difficulty on a GLP-1 is that appetite suppression makes any target harder to hit. Eating the protein portion first, at every meal, does more than adding a supplement at the end of the day.

Resistance training, twice a week. The Canadian Adult Obesity Clinical Practice Guidelines note that resistance training may support weight maintenance and modest increases in muscle or fat-free mass and mobility, and that regular aerobic activity favours maintenance of fat-free mass during weight loss. Two sessions a week covering the major muscle groups is the usual starting prescription. Bands and bodyweight work count.

The rate at which weight comes off also matters, since faster loss tends to cost proportionally more lean tissue. That is not something to adjust on your own. Dose, timing and any change to your treatment are conversations for the clinician who prescribes it — including if what you are weighing up is whether to continue at all, where the range of options may be useful background before that appointment. We prescribe and co-manage weight-loss medication here alongside the surgical side of the practice, so if you do not have a prescriber for that conversation, it is one you can have with us.

Frequently asked questions

Does everyone on a GLP-1 lose muscle?

Everyone losing weight at a meaningful rate loses some lean tissue, whatever the method. How much varies with age, sex, starting body composition, protein intake, activity and how fast the weight comes off. The trial averages are averages, not predictions for any individual.

Will I get the muscle back if I regain the weight?

Not necessarily in the same proportion. The weight-cycling literature suggests fat is restored ahead of lean tissue. Direct measurement of what tissue returns after stopping a GLP-1 specifically has not been reported from the large trials, so this remains an inference rather than a settled finding.

Should I stop my medication because of muscle loss?

That is a decision for you and your prescriber, and the evidence reviewed above does not point toward stopping. Untreated obesity carries its own risks, and expert reviews have not concluded that lean mass loss during treatment is harmful, while advising particular caution for older adults and for people who already have low muscle mass.

Is this a reason to have surgery instead?

No. Sleeve gastrectomy costs lean tissue in a similar range. Surgery and medication are different tools with different trade-offs, durability profiles and follow-up requirements, and neither is right for everyone. If you are weighing them, comparing medication and surgery sets out the considerations, and eligibility for surgery explains who is generally assessed. If you have already lost weight on a medication, that assessment looks at your current BMI, the highest BMI you have documented, and the trajectory across both, rather than a single reading on the day you come in — our calculator is a starting point, not a verdict. Where surgery is not the right fit, medical weight management is part of what we do as well.

Can I measure my own lean mass?

Not in a way that will tell you much. Home bioimpedance scales are not accurate enough to track this reliably, and the scans behind the figures above are research tools rather than something worth chasing down for yourself. For most people the more practical markers are strength and function: whether you can carry, climb and lift as well as you could six months ago.

Where this leaves you

Lean tissue comes off with fat whenever weight moves quickly — on a medication, on a diet, or after an operation. That is worth knowing, and it is worth planning around with protein and resistance training while the weight is coming off, rather than trying to recover ground later. It is not a reason to be frightened of an effective treatment, and it is not a reason to make a change on your own.

If you are somewhere in the middle of this — on a medication, coming off one, or trying to work out what comes next — a conversation is a reasonable next step. We prescribe and co-manage weight-loss medication as well as performing surgery, so the options our team can walk through include staying on treatment, coming off it with a plan for protecting lean tissue, and routes that do not involve an operation at all. When you are ready, book a consultation.

Consultations and surgery at The Sleeve Clinic are private-pay and not covered by OHIP. We see patients in Toronto and across the GTA, with virtual consultations available across Canada. You can read more about what a procedure costs and how patients finance it, or browse common questions.

Individual results vary. Consult with Dr. Gmora for a personalized assessment.

This article is general education about weight loss and body composition. It is not medical advice, and it cannot account for your health history, medications or circumstances. Nothing here should be used to start, stop, change or delay any treatment. Speak with your family physician, prescriber or bariatric team about your own situation, and seek urgent care for any acute symptoms.